Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
Swerdlow SH.
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):90-9. doi: 10.1182/asheducation-2014.1.90. Epub 2014 Nov 18.
IGH amplification in patients with B cell lymphoma unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt's lymphoma.
Bellone M, Zaslav AL, Ahmed T, Lee HL, Ma Y, Hu Y.
Biomark Res. 2014 May 9;2:9. doi: 10.1186/2050-7771-2-9. eCollection 2014.
Burkitt's Lymphoma and B-Cell Lymphoma Unclassifiable With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt's Lymphoma in Patients With HIV: Outcomes in a South African Public Hospital.
Sissolak G, Seftel M, Uldrick TS, Esterhuizen TM, Mohamed N, Kotze D.
J Glob Oncol. 2016 Aug 31;3(3):218-226. doi: 10.1200/JGO.2015.002378. eCollection 2017 Jun.
Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, Routbort MJ, Miranda R, Wang X, Qiao W, Medeiros LJ.
Cancer. 2012 Mar 15;118(6):1566-73. doi: 10.1002/cncr.26433. Epub 2011 Aug 31.
Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
Bürgesser MV, Gualco G, Diller A, Natkunam Y, Bacchi CE.
Ann Diagn Pathol. 2013 Jun;17(3):250-5. doi: 10.1016/j.anndiagpath.2012.11.001. Epub 2012 Dec 14.
Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Miyamoto K, Kobayashi Y, Maeshima AM, Taniguchi H, Nomoto J, Kitahara H, Fukuhara S, Munakata W, Maruyama D, Tobinai K.
Int J Hematol. 2016 Jun;103(6):693-702. doi: 10.1007/s12185-016-1989-z. Epub 2016 Apr 19.
Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
Maruyama D, Watanabe T, Maeshima AM, Nomoto J, Taniguchi H, Azuma T, Mori M, Munakata W, Kim SW, Kobayashi Y, Matsuno Y, Tobinai K.
Int J Hematol. 2010 Dec;92(5):732-43. doi: 10.1007/s12185-010-0728-0. Epub 2010 Dec 1.
MYC Negative Rectal B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt's Lymphoma in an Immunocompetent Patient.
Parikh JG, Strom T, Stone I.
Case Rep Pathol. 2013;2013:302304. doi: 10.1155/2013/302304. Epub 2013 Jan 14.
[B-cell lymphoma, unclassifiable, intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma].
Baryakh EA, Misyurina AE, Kovrigina AM, Misyurin VA, Kravchenko SK.
Ter Arkh. 2015;87(4):91-97. doi: 10.17116/terarkh201587491-97.
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Burkitt's lymphoma: A case report and review.
Chettiankandy TJ, Tupkari JV, Kumar K, Ahire MS.
J Oral Maxillofac Pathol. 2016 May-Aug;20(2):333. doi: 10.4103/0973-029X.185936.
